D-0853-2026 Class II Ongoing
FDA drug recall D-0853-2026 was initiated by Pfizer on Sep 4, 2026 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 23, 2026
- Initiation Date
- Sep 4, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
US Nationwide.
Code information
Lot # NL5230, Exp Date:10/2027
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0853-2026
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Pfizer? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.